Germany

Last Updated 25 May 2022.

5 Vaccines Approved for Use in Germany

• Novavax
  Nuvaxovid

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 37 countries

  16 trials in 12 countries

  Approval Source: ema.europa.eu

  Protein Subunit

• Moderna
  Spikevax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 86 countries

  63 trials in 22 countries

  Approval Source: ema.europa.eu

  RNA

• Pfizer/BioNTech
  Comirnaty

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 146 countries

  80 trials in 26 countries

  Approval Source: ema.europa.eu

  RNA

• Janssen (Johnson & Johnson)
  Ad26.COV2.S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 111 countries

  23 trials in 23 countries

  Approval Source: ema.europa.eu

  Non Replicating Viral Vector

• Oxford/AstraZeneca
  Vaxzevria

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 140 countries

  63 trials in 30 countries

  Approval Source: ema.europa.eu

  Non Replicating Viral Vector

16 Vaccines in Clinical Trials in Germany

• Clover
  SCB-2019

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  12 trials in 11 countries

  Protein Subunit

• Radboud University
  ABNCoV2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 2 countries

  VLP

• Pfizer/BioNTech
  BNT162b1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 3 countries

  RNA

• Pfizer/BioNTech
  BNT162b2s01

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 2 countries

  RNA

• Pfizer/BioNTech
  Comirnaty

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 146 countries

  80 trials in 26 countries

  RNA

• Janssen (Johnson & Johnson)
  Ad26.COV2.S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 111 countries

  23 trials in 23 countries

  Non Replicating Viral Vector

• ReiThera
  GRAd-COV2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 12 countries

  Non Replicating Viral Vector

• Tuebingen
  CoVac-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  3 trials in 1 country

  Protein Subunit

• Pfizer/BioNTech
  BNT162a1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162b2 (B.1.1.7 + B.1.617.2)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 4 countries

  RNA

• Pfizer/BioNTech
  BNT162b2 (B.1.1.7)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 4 countries

  RNA

• Pfizer/BioNTech
  BNT162b2 (B.1.617.2)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 4 countries

  RNA

• Pfizer/BioNTech
  BNT162b3

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162c2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Universitätsklinikum Hamburg-Eppendorf
  MVA-SARS-2-ST

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  3 trials in 1 country

  Non Replicating Viral Vector

• Universitatsklinikum Hamburg-Eppendorf
  MVA-SARS-2-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

1 Vaccines with Trials in Germany are No Longer Progressing

• Curevac
  CVnCoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  9 trials in 12 countries

  RNA